切除修复交叉互补基因1与消化系统肿瘤铂类耐药的关系研究进展

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (1): 116-120.

• 综述与讲座 • 上一篇

切除修复交叉互补基因1与消化系统肿瘤铂类耐药的关系研究进展

李笑秋, 胡冰

安徽医科大学附属省立医院肿瘤内科, 合肥230001, 安徽

收稿日期:2009-10-28 修回日期:2009-12-13 出版日期:2010-01-26 发布日期:2020-09-21
通讯作者: 胡冰, 女, 主任医师, 硕士研究生导师, 研究方向:消化系统肿瘤个体化化疗。Tel:0551-2283337 E-mail: razgrizlee2008@yahoo.com.cn
作者简介:李笑秋, 男, 在读硕士研究生, 研究方向: 消化系统肿瘤个体化化疗。Tel: 0551-2283337 E-mail: hubin3756@sina.com
基金资助:
安徽省自然科学基金(070413256X)

Advancement of the relationship ERCC1 and platinum resistance in digestive system malignant tumors

LI Xiao-qiu, HU Bing

Department of Oncology, Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, Anhui, China

Received:2009-10-28 Revised:2009-12-13 Online:2010-01-26 Published:2020-09-21

摘要/Abstract

摘要： 消化系统肿瘤由于其相对较高的发病率及死亡率, 危害日益突出, 故对消化道肿瘤治疗的研究具有相当的意义。铂类药物广泛用于恶性肿瘤的化疗, 是消化系统肿瘤化疗的传统药物之一, 但耐药性的产生严重影响其疗效, 目前认为核苷酸切除修复(nucleot ide ex cisio n repair, NER) 是铂类药物耐药的重要机制之一, 因其导致耐药的主要机理为清除大规模铂类化合物所致DNA 螺旋扭曲。其中核苷酸切除修复交叉互补基因1(excision repair cross comple/mentation group 1, ERCC1) 在NER 过程中发挥着重要作用, ERCC1 在消化系统肿瘤外周血及组织中的表达差异与含铂方案化疗的疗效存在着密切的联系。本文就ERCC1 的研究进展与消化系统肿瘤顺铂化疗疗效之间的关系进行综述。

关键词: 化疗, 铂类药物, 耐药, 核苷酸切除修复, 肿瘤

Abstract: Due to the high incidence and mortality of digestivesy stem malignant tumor, so it is of great significance to make further research for digestive tract tumor.Platinum drugs, one of the traditional drugs which is used for the chemo therapy for digestive system tumor, which has been extensively applied to the chemotherapy for malignant tumor.However, the resistance to the drug s exerts a serious influence on its curative effect.At present, it is believed that the nucleotide excision repair (NER) constitutes one of the most important mechanisms which results in the resistance to platinum drugs, mainly because it causes the twi sting of DNA helix by removing large numbers of platinum compounds. The nucleotide excision repair cross complementation group 1(ERCC1) plays an important role in the process of N ER.The different expression of ERCC1 in peripheral blood and tumor tissue of patients with digestive sysem tumor has a close connect ion with therapeutic effect of the platinum-containing chemotherapy.This article aims to provide an overview of the relation between the ERCC1 research development and the curative effect of cisplatin chemotherapy for digestive system tumor.

Key words: Chemo therapy, Platinu, Drugresi stance, Nucleotide excision repair, Tumor

中图分类号:

R735

李笑秋, 胡冰. 切除修复交叉互补基因1与消化系统肿瘤铂类耐药的关系研究进展[J]. 中国临床药理学与治疗学, 2010, 15(1): 116-120.

LI Xiao-qiu, HU Bing. Advancement of the relationship ERCC1 and platinum resistance in digestive system malignant tumors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 116-120.

参考文献

[1] Zamble DB, Llppard SJ. Cisplatin and DNA repair in cancer chemotherapy[J]. Trends Biochem Sci, 1995, 20(10): 435-439.
[2] Ahaha R, Llang X, Yu JJ, et al. Excision repair cross complementing-group 1: gene expression and platinum resistance[J]. Int J Mo l Med, 2004, 14(6): 959-970.
[3] Bermstein C, Bernstein H, Payne CM, et al. DNA repair/proapoptotic dual-role proteins in five major DNA repair pathway s: fail-safe pro tection against carcinogenesis[J]. Mutr Res, 2002, 5(11): 145-178.
[4] Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinatingag ents[J]. Cancer Treat Rev, 2007, 33(1): 9-14.
[5] Gazdar AF. DNA repair and survival in lung cancerthe two face s of Janus[J]. N Engl Med, 2007, 356(8): 771-776.
[6] Sugakawa K, Ng JMY, Matsutani C, et al. Xero derma pigmento sum group Cprotein complex is the initiator of global gene nucleo tide excision repair[J]. Mo LCell, 1998, 2(2): 223-232.
[7] 黄强, 陈忠平, 兰青, 等. 胶质瘤[M]. 中国科学技术出版社, 2000: 400-401.
[8] Gillet LC, Schrer OD. Molecular mechanisms of mamma liang lobal genome nucleotide excision repair [J]. Chem Rev, 2006, 106(2): 253-258.
[9] Britten RA, Liu D, Tessier A, et al. ERCC1 expression as a molecular marker of cisplatinr esistance in human cervical tumor cells [J]. Int J Cancer, 2000, 89(5): 453-458.
[10] Wilson MD, Ruttan CC, Koop BF, et al. ERCC1: a corn-pa rative genomic per spective[J]. Envir on Mol Mutagen, 2001, 38(2/3): 209-2l5.
[11] Kiyohara C, Yo shimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: A meta-analysis[J]. Int J Med Sci, 2007, 4(2): 59-71.
[12] Li YC, Gu SH, Wu QH, et al. No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis[J]. Eur J Hum Genet,2007, 15(9): 967-973.
[13] Wei Q, Frazier M L, Levin B. DNA repair: a double 2edged sword[J]. J Natl Cancer Inst, 2000, 92(6): 440-441.
[14] Joshi MB, Shirota Y, Danerberg KD, et al. High gene expression of TS1, GS TP1 and ERCC1 are risk factors for survival in patients treated with trimodality the rapy for esophageal cacer[J]. Clin Cancer Res, 2005, 11(8): 2215-2221.
[15] Brabender J, Vallbohmer D, Grimminger P, et al. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus[J]. J Gastr ointest Surg, 2008, 12(11): 1815-1821.
[16] Warnecke-Eberz U, Vallbö hmer D, Alakus H, et al. ERCC1 and XRCC1 Gene Polymorphisms 17 Predict response to neoadjuvant radio chemo therapy in esophageal cancer[J]. Predict response to neo adjuv ant radio chemo therapy in esophageal cancer[J]. J Ga strointest Surg, 2009, 13(8): 1411-1421.
[17] Kwon HC, Roh M S, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathioneS-transfe rase Plfor 5-fluo rouracil/oxaliplatin chemo therapy in advanced gastric cancer[J]. Ann Oncol, 2007, 18(3): 504-509.
[18] Wei J, Zou Z, Qian X, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen [J]. Br J Cancer, 2008, 9(8): 1398-1402.
[19] 黄朝晖, 华东, 李莉华, 等, ERCC1 m RNA 表达及基因多态性对胃癌辅助化疗预后的影响[J]. 南京医科大学学报:自然科学版, 2008, 28(4): 453-456.
[20] Chang PM, Tzeng CH, Chen PM, et al. ERCC1 co do n 118 CT polymorphism associated ERCC1 expression and outcome of FOLFOX-4 with treatment in Asian patients with metastatic colorectal carcinoma20] Chang PM, Tzeng CH, Chen PM, et al. ERCC1 codon 118 CT polymorphism associated ERCC1 expression and outcome of FOLFOX-4 with treatment in Asian patients with metastatic colorectal carcinoma[J]. Cancer Sci, 2009, 100(2): 278-283.
[21] Iqbal S, Lenz H J. Molecular predictors of treatment and outcome in co lo rectal cancer[J]. Curr Gastr oenterol Rep, 2003, 5(5): 399-405.
[22] Kamikozur u H, Kuramochi H, Hayashi K, et al. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemo therapy[J]. Int J Onco l, 2008, 32(5): 1091-1096.

切除修复交叉互补基因1与消化系统肿瘤铂类耐药的关系研究进展

Advancement of the relationship ERCC1 and platinum resistance in digestive system malignant tumors

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王如玥, 谢飞, 王欣, 李红玉. 脾多肽注射液对化疗后KM小鼠骨髓抑制和免疫力低下的治疗作用[J]. 中国临床药理学与治疗学, 2023, 28(9): 1000-1007.
[2]	姜道利, 丑晓华, 刘志东, 李薇, 张波, 许桑, 谈德斐, 方翼, 吕冬梅, 王涛. 头孢他啶阿维巴坦治疗多重耐药革兰阴性菌感染的真实世界研究[J]. 中国临床药理学与治疗学, 2023, 28(9): 1008-1017.
[3]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[4]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[5]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[6]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[7]	李爽, 韩淑贞, 戴瑜婷, 修明慧, 杜籼芹, 和建政, 蔺兴遥. 基于多种化疗肠损伤发生机制的中医药防治进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 583-593.
[8]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[9]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[10]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[11]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[12]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[13]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[14]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[15]	刘丹, 刘明, 金良友, 潘娟, 辛昊儒, 刘梦圆, 李鑫, 郑坤, 冯晓灵. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1168-1176.